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Nitric Oxide Synthase Inhibition Enhances the Antitumor
Effect of Radiation in the Treatment of Squamous
Carcinoma Xenografts
Robert J. G. Cardnell*, Ross B. Mikkelsen
Department of Radiation Oncology, Virginia Commonwealth University, Richmond, Virginia, United States of America
Abstract
This study tests whether the nitric oxide synthase (NOS) inhibitor, NG-nitro-L-arginine (L-NNA), combines favorably with
ionizing radiation (IR) in controlling squamous carcinoma tumor growth. Animals bearing FaDu and A431 xenografts were
treated with L-NNA in the drinking water. IR exposure was 10 Gy for tumor growth and survival studies and 4 Gy for ex vivo
clonogenic assays. Cryosections were examined immunohistochemically for markers of apoptosis and hypoxia. Blood flow
was assayed by fluorescent microscopy of tissue cryosections after i.v. injection of fluorospheres. Orally administered L-NNA
for 24 hrs reduces tumor blood flow by 80% (p,0.01). Within 24 hrs L-NNA treatment stopped tumor growth for at least 10
days before tumor growth again ensued. The growth arrest was in part due to increased cell killing since a combination of L-
NNA and a single 4 Gy IR caused 82% tumor cell killing measured by an ex vivo clonogenic assay compared to 49% by L-
NNA or 29% by IR alone. A Kaplan-Meyer analysis of animal survival revealed a distinct survival advantage for the combined
treatment. Combining L-NNA and IR was also found to be at least as effective as a single i.p. dose of cisplatin plus IR. In
contrast to the in vivo studies, exposure of cells to L-NNA in vitro was without effect on clonogenicity with or without IR.
Western and immunochemical analysis of expression of a number of proteins involved in NO signaling indicated that L-NNA
treatment enhanced arginase-2 expression and that this may represent vasculature remodeling and escape from NOS
inhibition. For tumors such as head and neck squamous carcinomas that show only modest responses to inhibitors of
specific angiogenic pathways, targeting NO-dependent pro-survival and angiogenic mechanisms in both tumor and
supporting stromal cells may present a potential new strategy for tumor control.
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Introduction
Nitric oxide synthase (NOS) activity is a key component in a
number of survival mechanisms integrated into the autocrine and
paracrine nature of tumor cells and supporting stromal cells. For
example, the catalytic activities of protein tyrosine phosphatases
such as SHP-2 that modulate the receptor tyrosine kinases (RTK)
are modulated by S-nitrosylation and oxidation of their active site
cysteine [1,2]. The basal activities of other key regulatory proteins
such as the transcription factor, NF-kB, are also sensitive to nitro-
oxidative stress. NF-kB and as a consequence a number of its
target cytoprotective genes are constitutively activated in numer-
ous cancers including head and neck squamous cell carcinomas
(HNSCC) cell lines and tissues [3,4,5]. In vitro experiments with
different cell types have demonstrated that 30–50% of the basal
NF-kB activity is sensitive to either NOS inhibitors or dominant
negative NOS mutants [6].
These NOS-dependent survival mechanisms are also activated
by ionizing radiation (IR). For example, (IR) stimulates the activity
of eNOS (NOS-3) in tumor endothelial cells resulting in enhanced
tumor angiogenesis through RTK-dependent and –independent
mechanisms [7,8,9]. IR also stimulates NOS activity in tumor cells
activating diverse anti-apoptotic mechanisms involving RTK and
NF-kB signaling pathways. In mutant Ras transformed cells, Akt
phosphorylation and activation of eNOS results in the S-
nitrosylation (or oxidation to sulfenic acid) of Ras Cys118,
enhancing GTP binding, and thereby stimulating cytoprotective
signaling pathways [10]. In vitro experiments have shown that
activation of these NF-kB and RTK ‘‘pro-survival’’ mechanisms
by IR can be inhibited by the NOS inhibitor NG-nitro-L-arginine
(L-NNA) [6,7].
Previous studies of fibrosarcoma type II and hepatocarcinoma
transplantable liver tumors have shown that the L-NAME (the bio-
inactive pro-drug of L-NNA) has no effect upon short term tumor
oxygenation following 4 Gy IR but inhibits an increase in tumor
pO2 observed 24 hours post irradiation [11,12]. Short-term
administration of L-NAME also does not add to the delay of tumor
growth seen with a single dose of IR [11,13]. These and similar
studies have not, however, studied the effects of long term NOS
inhibition upon tumor growth or cell killing, nor have they utilized
the active drug, L-NNA. This fully active NOS inhibitor, L-NNA,
selectively reduces the blood flow to P22 carcinosarcomas in BD9
rats [7,14]. Furthermore, a clinical phase I dose escalation study
demonstrated that a single i.v. dose of L-NNA decreases tumor
vascular blood volume by 40%, an effect that is sustained 24 hours
post-treatment with minimal side effects (toxicity level 1) [15].
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Recent studies have also examined whether the anti-tumor
activity of the vascular disrupting agent, combrestatin A-4 3-O-
phosphate is enhanced by the co-administration of L-NNA
[16,17]. The combination of the two vascular targeting agents
achieved therapeutic enhancement over either agent alone as
measured by tumor growth delay. The combination of two
systemic anti-vascular agents is potentially very toxic to normal
tissues. For this reason we investigated whether L-NNA treatment
interacts favorably with a second targeted anti-tumor therapy,
radiation. From a radiobiological perspective, radioresistance is
associated with acute hypoxia. However, prolonged or chronic
hypoxia (.72 hr) has been shown in some in vitro studies to
enhance cellular radiosensitivity by a mechanism involving
inhibition of cell energy metabolism and as a consequence
inhibition of DNA repair mechanisms [18,19]. Here we report
that the addition of L-NNA to drinking water of tumor-bearing
animals delays tumor growth, elicits tumor cell killing through
apoptosis, preferentially reduces tumor blood volume and, when
combined with a single 10 Gy IR dose, enhances animal survival.
These observations suggest that anti-NOS agents in combination
with IR can be therapeutically beneficial in the treatment of
squamous carcinomas.
Methods
Cell culture
A431 and FaDu cells from the American Type Culture
Collection (Manassas, VA) were maintained in RPMI 1640
medium supplemented with 10% fetal bovine serum at 5%
carbon dioxide in a humidified 37uC incubator. For hypoxia
studies cells were plated under normoxic conditions and
subsequently moved to a hypoxic glove box (Coy Laboratory
Products, Inc) where they were equilibrated at low oxygen levels
for 1 hour before being placed in billups-rothenburg chambers
incubated at 37uC. In vitro clonogenic assays followed protocols
established elsewhere [19].
Mouse xenograft model
Tumor xenografts were created by the subcutaneous injection of
106 A431 or 56105 FaDu cells suspended in sterile saline into the
hind flanks of 5–6-week-old athymic NCr-nu/nu male mice.
Tumor dimensions were calculated three times weekly from
caliper measurements of the tumor made using the formula
width26length60.4 (where the width is the smaller dimension).
The mice designated for treatment with the NOS inhibitor were
provided with drinking water supplemented with 0.5 g/L L-NNA
(Sigma-Aldrich, St. Louis, MO). Fresh L-NNA-containing water
was provided three times weekly. Mice were obtained from the
National Cancer Institute (Frederick, MD). Animals designated for
cisplatin treatment received a single 8 mg/kg in sterile saline bolus
i.p. on day 0 prior to initiation of L-NNA treatment, but no more
than 24 hours prior to irradiation [20]. All procedures were
approved by the Institutional Animal Care and Use Committee of
Virginia Commonwealth University and conformed to the
guidelines established by the National Institutes of Health,
protocol numbers AM10080 and AM10185.
In vivo radiation treatment
Mice were anaesthetized with ketamine/xylazine. The irradi-
ation beam from a clinically retired Picker 60Co source was
focused on the posterior legs to minimize irradiation of the
abdomen. Radiation exposure was 10 Gy for tumor growth and
animal survival assays. For the ex vivo clonogenic assay the single
radiation dose was 4 Gy.
Ex vivo clonogenic cell survival assay
Twenty-four hours post-irradiation or post L-NNA-treatment,
tumors were harvested and cells derived therefrom were plated for
colony formation assays as previously described [21].
Blood flow analysis
When A431 xenografts reached the size of approximately
150 mm3, half the mice received drinking water supplemented
with L-NNA. Twenty-four hours later 0.25 ml of 0.1 mm diameter
blue FluoSphere beads (Invitrogen, Carlsbad, CA) diluted 1:6 in
physiological saline was delivered by tail vein injection [22]. Three
minutes post-injection the animals were sacrificed and the tumor,
heart, liver, spleen and kidney excised, flash frozen and embedded
in OCT (Sakaru, Torrance, CA) for cryosectioning. Cryosections
of 8 mm thickness were examined by direct fluorescent microscopy
at 106magnification. Five randomly selected frames from each
cryosection were quantified using ImageJ (NIH).
Immunohistochemistry
Tumors were excised from animals and immediately flash
frozen in liquid N2, embedded in OCT and 6 mm cryosections
prepared. Apoptosis was assayed using the ApoptagTM (Millipore,
Billerica, MA) kit as per the manufacturer’s instructions.
Areas of hypoxia were identified and quantified by three
staining procedures (exogenous pimonidazole and endogenous
HIF1a and CA-9 expression). Pimonidazole HCl (HPI Inc.,
Burlington, MA) was injected i.p. (200 mg/kg in sterile saline). At
3 hours post injection tumors were excised, frozen, and prepared
for immunohistochemical analysis. Cryosections were fixed in 4%
paraformaldehyde, permeabilized in 0.25% Triton, endogenous
peroxidase quenched with 3% H2O2 in 10% methanol, and
blocked with 10% normal donkey serum. Immunostaining was
performed by overnight incubation with rabbit anti-pimonidazole
antisera (PAb2627, Hydroxyprobe, Inc.), rabbit anti-carbonic
anhydrase IX (1:100, ab15068, AbCam, Cambridge, MA) and
rabbit anti-HIF1a (Pre-diluted, ab76471, AbCam) primary
antibodies. An HRP conjugated anti-rabbit secondary antibody
(2 mg/ml, Rockland Immunochemicals, Gilbertsville, PA) followed
by 5 minute 3,39-Diaminobenzidine (DAB) was used to indicate
hypoxic cells; hemotoxylin was used as a counterstain. Images of
stained sections were captured and analyzed using the Ariol high
throughput histopathology system (Genetix USA, Inc., Boston,
MA). The Ariol system quantifies positive staining using color and
shape classifiers to analyze the entirety of each section imaged.
Analysis with the classifiers can be used to count shapes (e.g.
nuclei) of predetermined sizes and colors or areas of particular
colors allowing for calculations of percentage of nuclei that stain
positive or area that stains positive. The threshold for positive
staining was established using sections stained without the primary
antibody.
For Hematoxylin and Eosin staining, cryosections (10 mm) were
fixed in 4% paraformaldehyde, submerged in Modified Mayer’s
Hematoxylin (Richard Allan Scientific), destained in acid ethanol,
stained with eosin, dehydrated and mounted with permount.
Images were captured and analyzed using the Ariol system.
Western blot
Protein was extracted from flash frozen tumors using a pestle
and mortar and 20 ml/g tumor RIPA lysis buffer (50 mM Tris-
HCL pH 7.5, 10 mM NaCl, 1% Triton X-100, 1% sodium
deoxycholate, 0.1% SDS, 5 mM EDTA) and processed under
reducing conditions. Proteins were resolved with 8% resolving
SDS-polyacrylamide gel electrophoresis and transferred to nitro-
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cellulose membranes. Membranes were incubated with dilutions of
1:1000 of arginase II, iNOS or actin antibodies (Santa Cruz
Biotechnology, Santa Cruz, CA) overnight at 4uC. Blots were
developed using IR 700 or IR 800 conjugated secondary
antibodies (Rockland Immunochemicals, Gilbertsville, PA) diluted
1:10,000 and imaged/analyzed using the Odyssey Licor system.
Statistics
Statistical significance calculated using un-paired student t-tests
for all assays other than animal survival where log-rank analysis
was performed. Thresholds for statistical significance are indicated
in the text. Variances are presented as the standard error of the
mean. ‘‘N’’ values indicate the number of animals used; ‘‘n’’ values
the number of tumors.
Results
L-NNA delays A431 and FADU xenograft growth
To determine the effect of L-NNA on the growth of tumors,
xenografts were grown unhindered until approximately 150 mm3
in volume, at which point they were divided into four treatment
groups: control; 0.5 g/L L-NNA in drinking water from day 0;
10 Gy IR on day 1; or L-NNA from day 0 and 10 Gy IR on day 1.
Tumor growth delay was determined by the average tumor
volume relative to treatment day 0 for each group (Fig. 1A) and by
the time for the tumor volume to triple relative to treatment day 1
(Fig. 1B). Both the L-NNA and L-NNA plus IR treatments were
effective in delaying A431 tumor growth compared to control non-
treated and irradiated alone tumors. The combined treatment
caused a growth delay significantly longer than either treatment
alone.
A similar set of experiments was performed with FaDu
xenografts to evaluate if the inhibitory effect of L-NNA on tumor
growth could be generalized to another tumor. Tumor growth was
assayed by average tumor volume (Fig. 1C) and tripling time
(Fig. 1D). All three treatments delayed tumor growth compared to
control with the combined treatment being the most effective. The
delay observed in FaDu xenografts was greater than that observed
in A431 xenograft-bearing animals.
We also tested the methyl ester pro-drug of L-NNA, Nv-nitro-
L-arginine-methyl ester (L-NAME). L-NAME (0.5 g/L in drinking
water) elicits a much shorter delay in the growth of both A431 and
FaDu xenografts (49% and 27% increase in tripling time over
control respectively). L-NAME must be hydrolyzed to L-NNA in
order to become bioactive and this requirement for processing
may limit bioavailability of L-NNA [23].
Figure 1. L-NNA and IR reduce the rate of xenograft growth. Relative volumes of differently treated A431 (A) and FaDu (C) xenografts. Mean
tripling time of A431 (B) and FaDu (D) xenografts. Xenografts were created in athymic nu/nu mice by subcutaneous injection of 106 A431 or 56105
FaDu cells into the hind flank, once tumors were established animals were divided into 4 groups as indicated. L-NNA was provided from day 0 at
0.5 g/L in drinking water, irradiated animals received a single 10 Gy dose targeted at the flank using a 60Co source on day 1. Data presented as mean
relative volume 6 SEM or mean days to triple volume 6 SEM; N= 5, n = 10. * = p,0.05, *** = p,0.01. Horizontal lines and accompanying asterisks
indicate statistically significant differences.
doi:10.1371/journal.pone.0020147.g001
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L-NNA plus IR increases survival
During the analysis of the growth of FaDu xenografts, it became
apparent that animals receiving both L-NNA and IR outlived their
counterparts receiving either no or mono-therapies. As shown in
Figure 2 the combined L-NNA plus IR treated animals survived
significantly longer than the control, IR only or L-NNA only
groups. Median survival was increased to 37.5 days in animals
receiving both L-NNA and IR as compared to 20 days
(p = 0.00007) for control animals, 23.5 days (p = 0.003) for animals
receiving only IR and 27 days (p = 0.26) for the L-NNA alone
group. To further quantify the significance of the combined
treatment we calculated the enhancement factor [24]. Enhance-
ment factors of greater than 2.5 were determined for both FaDu
xenograft tripling time and animal survival indicating the
combined L-NNA and IR treatment to be more than the additive
effect of the individual treatments. While a reduced tumor burden
undoubtedly plays a role in enhanced survival, that either IR or L-
NNA alone is sufficient to reduce the rate of FaDu xenograft
growth but not to significantly enhance survival suggests other
mechanisms might be involved. Possible mechanisms are discussed
more fully below.
L-NNA induces tumor cell killing
Having shown L-NNA to slow xenograft growth and L-NNA
plus IR to enhance survival, ex vivo clonogenic assays with A431
xenografts were performed to determine what proportion of tumor
cells are killed within the first 24 hrs of each treatment. As shown
in Figure 3, 4 Gy IR or overnight L-NNA alone result in 29% and
49% respectively fewer colonies formed as compared to control.
The combination of overnight L-NNA consumption followed by
IR, however, elicited an 82% reduction in the number of colonies
formed compared to untreated controls. These results show L-
NNA by itself caused significant tumor cell killing compared to
untreated controls in vivo. However, in vitro clonogenic assays using
A431 monolayers exposed continuously to L-NNA concentrations
up to 100 mM failed to show any decrease in clonogenicity. This in
vitro finding suggests that other mechanisms possibly involving the
tumor cell microenvironment come into play for L-NNA to have it
cytotoxic effects on the tumor cells in vivo.
L-NNA treatment induces apoptosis
Since it has been shown that L-NNA inhibits basal and IR-
induced anti-apoptotic signaling pathways such as NF-kB [6], we
tested whether L-NNA treatment enhanced apoptosis in vivo.
Cryosections from tumors following 0 and 1 day of L-NNA
treatment were stained by immunohistochemistry for 39OH DNA
terminus as a measure of apoptosis. Analysis of sections from
multiple experiments shows a significant increase in the number of
cells staining positive for apoptosis following 1 day of L-NNA
treatment. At Day 1 a 4.4 fold (61.7, p = 0.04) increase over day 0
in the proportion of apoptotic cells is observed. The increased
apoptosis provides one explanation for the rapid induction of
growth delay seen with L-NNA treatment (Figure 1A).
L-NNA preferentially reduces tumor blood flow
In both humans and rats intravenous introduction of L-NNA
induces a reduction in tumor blood flow [14,15]. We tested
whether this also occurs in mice with L-NNA delivered in the
drinking water for 24 hours. Tissues from animals bearing a single
A431 flank xenograft were excised 3 minutes after tail vein
injection of fluorescent beads and subsequently analyzed by direct
fluorescent microscopy to determine the degree to which the beads
had penetrated each tissue (Figure 4). Whereas L-NNA causes
some reduction in blood flow in all tissues analyzed, the only
statistically significant decrease is in the tumor (.80%, p,0.01).
We tested the possibility of increased tumor hypoxia with
immunohistochemical analysis for markers of hypoxia in tumors
following 0, 1 and 6 days of L-NNA treatment. Pimonidazole,
carbonic anhydrase IX (CA-9) and HIF1a are established markers
of hypoxia. Figure 4 shows the proportion of cells staining positive
for pimonidazole to increase significantly following L-NNA
treatment (17.7% to 24.1%, p,0.05, Figure 4C) suggesting that
the hypoxic volume of the tumors is increased. The CA-9 and
HIF1a markers (Figure 4D) do not show a significant increase
following L-NNA treatment. As discussed below the insensitivity of
the endogenous hypoxia markers may reflect their low dynamic
response range to oxygen concentration compared to pimonida-
zole and their complex responses to tumor microenvironment
including NO.
Based on the results with pimonidazole we tested the effect of
chronic hypoxia (.72 hrs) on the radio-sensitivity of A431 cells in
vitro. We expected, based on previous reports, that chronic
hypoxia, as opposed to acute hypoxia, might actually radiosensi-
tize [18,19]. However, as shown in Figure 5B, similar long-term
Figure 2. L-NNA with IR enhances animal survival. Survival of
differently treated FaDu xenograft bearing mice. Kaplan-Meyer survival
plot of animals receiving either no treatment; 10 Gy IR; L-NNA; or L-NNA
and 10 Gy IR. Animals receiving L-NNA and IR survived significantly
longer than all other groups as determined by log-rank analysis (p,.05,
N$29).
doi:10.1371/journal.pone.0020147.g002
Figure 3. L-NNA reduces cell survival. Clonogenic survival of A431
cells isolated from flank xenografts following the treatments indicated.
Data presented as mean colonies formed as a percentage of control 6
SEM; N= 3, n = 6.
doi:10.1371/journal.pone.0020147.g003
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hypoxic conditions with A431 cells actually induced radio-
resistance in vitro, whereas acute hypoxia had no effect on
radiosensitivity (Figure 5A). These results suggest the effects of
L-NNA in vivo are not simply the result of hypoxia.
Arginase II but not iNOS expression increases following
L-NNA treatment
L-arginine, the substrate for NOS, is also metabolized by
arginase to produce urea and L-ornithine. It has been proposed
that a switch from the metabolism of arginine by NOS to arginase
is part of the transition of the inflammatory response from the
early NO-driven ‘‘anti-bacterial’’ phase to the later polyamine
dependent repair phase [25,26]. Arginase II expression increases
in pulmonary arterial smooth muscle cells under hypoxic
conditions [27]. The upregulation of arginase II expression has
also been implicated in smooth muscle cell growth and collagen
synthesis, suggesting a role in aberrant vessel wall remodeling [27].
Given these findings and that the inhibition of NOS is likely to
result in an accumulation of L-arginine, we determined the
expression of arginase II in A431 xenografts prior to and following
L-NNA treatment. As shown in figure 6, there is little arginase II
expressed prior to L-NNA treatment. Expression increased
starting 1 day post treatment with L-NNA and continuing with
a statistically significant increase observed at day 6. Immunohis-
tochemical analysis of tumor sections for arginase II expression
showed expression in a majority of cells at all three time points
(data not shown). Since most cells express arginase II, the observed
increase in arginase II expression is due to either increased
expression or decreased degredation in individual cells rather than
an increase in the number of cells that express arginase II. The
timing of the increased arginase II expression may be particularly
pertinent. Arginase catalyzes arginine to ornithine conversion, an
important step in polyamine synthesis and which has been shown
to promote tumor growth and survival [28].
A previous in vitro study with EMT-6 tumor cells demonstrated
increased expression of iNOS following 24 hours of 1% O2 [29].
Western blot analysis of A431 tumor lysates for iNOS showed
minimal basal expression in the xenografts and no meaningful
change in iNOS expression with L-NNA treatment.
L-NNA treatment is comparable to single bolus cisplatin
treatment
We compared the effectiveness of L-NNA treatment relative to,
and in combination with, cisplatin. Flank FaDu xenograft-bearing
animals were treated with either: cisplatin; cisplatin and IR;
cisplatin and L-NNA; or cisplatin, L-NNA and IR. A treatment
modality whereby animals received a single large bolus i.p. of
cisplatin was used as this modality has been shown to effective in
vivo and was most compatible with our existing L-NNA and IR
treatment plan [20]. The animals were monitored for tumor
volume and survival. As seen in Figure 7, the delay in tripling of
the tumor volume and the enhancement of survival observed
following L-NNA with IR is equal to the effect of single bolus
cisplatin with IR. Interestingly, the triple treatment provided no
significant advantage over either L-NNA and IR or single bolus
cisplatin and IR; indeed the triple treatment was highly toxic with
30% mortality by day 10 post-treatment.
Discussion
Analyses of tumor growth delay, animal survival and ex vivo
clonogenicity show that L-NNA when combined with IR to be
highly effective in controlling squamous carcinoma xenografts. L-
NNA alone is not without benefit and is as effective as a single
4 Gy IR dose when evaluated by ex vivo clonogenic assay 24 hrs
post treatment. L-NNA by itself kills tumor cells in vivo, in part
through promoting apoptosis. It is, however, not entirely clear if
increased tumor cell apoptosis accounts for the total effect of L-
NNA. Differentiation of some tumor cells can also explain the
Figure 4. L-NNA treatment decreases tumor blood flow and
increases hypoxia. Comparison of tissue vasculature from L-NNA
treated and control mice. Example direct fluorescent images from
control and L-NNA treated A431 tumors (A). Quantification of decreased
blood flow to tumors and other tissues following L-NNA treatment (B).
Blood flow was determined by tissue penetration of i.v. injected
fluorescent beads within 3 minutes of injection. Data presented as
mean intensity as a percentage of control 6 SEM; n= 5; *** = p,0.01.
A431 tumor hypoxia following L-NNA treatment measured immuno-
histochemically by pimonidazole (C), carbonic anhydrase IX and HIF-1a
expression (D).
doi:10.1371/journal.pone.0020147.g004
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results observed and A431 and FaDu cell types are prone to
differentiation through cornification, particularly following IR
[24,30]. Histopathological analysis of L-NNA treated tumors,
however, shows no increase in differentiation. Similarly, no
significant increase in areas of necrosis is observed following L-
NNA treatment. A previous study also did not observe increased
necrosis with L-NNA treatment [16]. The decreased blood flow to
the tumor with L-NNA treatment and corresponding decrease in
nutrient supply to the tumor suggests that autophagy may also
contribute. Autophagy under stress is considered a damage
limitation program from which cells can escape once ‘‘normal’’
conditions are restored; this may account for why the growth of
the tumor is delayed and not halted. Previous studies have also
established that autophagy radiosensitizes some tumor cells
[31,32].
The L-NNA-induced decrease in tumor blood flow observed in
Figure 4 results in increased tumor hypoxia when measured by
pimonidazole staining, the gold standard in assays for tumor
hypoxia in situ. We also stained tumor sections for endogenous
markers of hypoxia, HIF-1a and CA-9. Both these markers did not
respond to L-NNA treatment which is not that surprising given
their low dynamic response range to changes in tumor oxygen
levels. For example, HIF-1a is stabilized at oxygen concentrations
as high as 6% [33]. Consequentially large areas of untreated
tumor will stain positive for both HIF-1a and CA-9. Endogenous
markers are also sensitive to microenvironmental changes
independent of oxygen concentration, e.g. NO [34]. That CA-9
is also non-responsive to L-NNA treatment probably reflects the
fact that HIF-1a regulates CA-9 expression [35].
Endothelial cell generated NO mediates relaxation of vascular
smooth muscle and thus, in normal tissues, inhibition of eNOS can
cause hypoxia by decreasing vasodilation and enhancing vaso-
constriction [36,37]. Because of their disorganized and poorly
functional vasculature, most tumors have regions of intermittent
hypoxia that contain viable cells. However persistent inhibition of
endothelial cell eNOS with continuous exposure to a NOS
inhibitor can convert a state of intermittent hypoxia to one that is
chronic with the consequences very different from acute,
intermittent hypoxia. In evaluating mechanisms underlying the
effects of chronic hypoxia on cell activities investigations have been
confined to in vitro analyses to permit defined levels of oxygenation.
These studies have demonstrated that in vitro proliferation of tumor
cells is unhindered by chronic hypoxic conditions as low as 0.2%
oxygen [19]. Our own unpublished studies with A431 and FaDu
cells have confirmed this. However, expression of homologous
recombination DNA repair proteins is partially suppressed in some
cells chronically exposed to low oxygen. There is a corresponding
decrease in error free DNA repair and corresponding radiosen-
sitization and sensitization to DNA damaging drugs [19]. This
possibly provides one explanation for why chronic hypoxia, in
contrast to acute hypoxia, also radiosensitizes cells [18,19].
However, we were unable to demonstrate in in vitro clonogenic
assays using A431 cells radiosensitization using near identical low
oxygen levels and length of hypoxia (Figure 5 A & B). The effects
of prolonged hypoxia in vitro may be cell type specific.
Results from in vitro clonogenic assays testing the effects of
hypoxia are only indicative of possible changes in oxygen delivery
and do not reflect other consequences of reduced blood flow such
as the disruption of nutrient delivery and waste disposal which
may also contribute to radiosensitization. As shown in previous
studies inhibiting glycolysis can be both cytostatic and cytotoxic
[38,39]. 2-deoxyglucose, for example, inhibits cell cycle progres-
sion and is cytotoxic to tumor cells especially under hypoxic
conditions. Induction of chronic hypoxia may also suggest why L-
Figure 5. Chronic hypoxia and radiosensitivity in vitro. A431 cells cultured under normoxic and chronic hypoxic condition show decreased
sensitivity to irradiation following long-term hypoxia. 24 hour hypoxic incubation (0.5% O2) prior to 4 Gy irradiation has no effect upon cell survival
(A). Chronic (72 hour) hypoxia decreases radiosensitivity at 5 and 10 Gy, but reoxygenation for 6 hours prior to IR restores radiosensitivity (B). Data
presented as mean surviving fraction 6 SEM. In all cases cells were plated in triplicate at two cell densities.
doi:10.1371/journal.pone.0020147.g005
Figure 6. Arginase II expression increases following L-NNA
exposure. Western blots of arginase II and actin expression in A431
xenografts prior to and following 1 and 6 days of L-NNA treatment (A).
Quantification of relative arginase II expression standardized to actin
(B). Data presented as mean 6 SEM; n = 3, * = p,0.05.
doi:10.1371/journal.pone.0020147.g006
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NNA is cytotoxic in vivo but not in vitro beyond invoking an
exclusively antiangiogenesis mechanism. In vitro studies have
demonstrated that inhibition of NOS with L-NNA can block
important cytoprotective mechanisms such as such as ras/Akt
pathways and NF-kB signaling [2,6,10]. Blocking these NO-
sensitive cytoprotective mechanisms, however, may only result in
cell killing under hypoxic stress conditions. This is currently under
study.
The administration of L-NNA elicits only a temporary restraint
upon tumor growth indicating some compensatory mechanism is
activated resulting in resumed tumor growth (Figure 1). In terms of
tumor endothelial cell proliferation one such mechanism is an
‘‘angiogenic switch’’ whereby blocking of one angiogenic pathway
is compensated by the activation of an alternative angiogenic
pathway [40]. Our finding of enhanced arginase II expression with
NOS inhibition by L-NNA treatment suggests one such compen-
satory pathway. We have not, however, observed any increase in
CD31 positive staining or structures to accompany increased
angiogenesis. This does not preclude an increase in CD31 negative
nascent vasculature [41]. Previous studies have established that
hypoxia induces expression of arginase II in diverse cell types
including endothelial and vasculature smooth muscle cells and that
over expression of arginase II stimulates endothelial cell
proliferation [27,42]. There also appears to be a reciprocal
relationship between NOS expression and arginase II expression
at least in some cell types [26,42]. The enhanced arginase II
expression we observe with prolonged L-NNA treatment may
represent a growth promoting compensatory mechanism [28].
Other investigators have tested NOS inhibitors as anti-tumor
agents, often with less efficacious results than seen in the present
study. For example, L-NNA delivered i.p. 30 minutes prior to
20 Gy IR in mice bearing murine transplantable tumors induced
full radiobiological hypoxia and increased tumor cell clonogenicity
[43]. L-NAME delivered i.p. 1 hour prior to IR does not enhance
a 16 Gy dose in delaying the growth of FsaII murine fibrosarco-
mas [13]. Similarly, L-NAME added to drinking water blocks an
increase in pO2 seen 24 hrs post IR, does not enhance the effect of
6 Gy IR in murine transplantable liver tumors (TLT), and
abolishes the effect of a second dose of IR [11]. Overnight
treatment with L-NAME in the drinking water of FsaII or TLT
bearing animals has no effect upon tumor pO2 4 hrs after 4 Gy IR
[12]. Our experimental approach differs significantly from many
Figure 7. L-NNA treatment is comparable to cisplatin. L-NNA with IR is seen to be as, or more, effective than any other treatment in A431
xenografts. Flank xenograft tripling time following the treatments indicated (A). Data presented as mean 6 SEM. Median survival times of animals
bearing flank xenografts following the treatments indicated (B). Significance calculated by log-rank analysis. Cisplatin delivered as a single i.p. bolus at
8 mg/kg on day 0; L-NNA provided from day 0 at 0.5 g/L in drinking water; irradiated animals received a single 10 Gy dose targeted at the flank using
a 60Co source on day 1. (* = p,0.05, ** = p,0.02, *** = p,0.01).
doi:10.1371/journal.pone.0020147.g007
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of these studies in that we use L-NNA rather than L-NAME, we
treat with L-NNA overnight prior to IR and continue to provide
L-NNA for the duration of the experiment. Furthermore, we were
not able to replicate our L-NNA data using L-NAME in our
model. Not all tumor types appear as responsive to NOS inhibition
as squamous carcinomas [13,44]. NO can act to both promote and
inhibit tumor progression and metastasis depending upon NOS
activity, isoforms present, concentration and duration of NO
exposure and cellular sensitivity to NO [45].
Previous studies have combined IR with therapies targeting
specific mechanisms (e.g. angiogenesis [46]) or specific molecular
targets (e.g. VEGFR [47]). For the most part these strategies have
proven only marginally effective in radiotherapy of head and neck
squamous carcinomas [48]. L-NNA represents an agent that acts
with minimal side effects but in a more general manner to affect
multiple cellular survival mechanisms in both tumors and the
supporting stroma. For example, by mitigating the activity of the
PI3K-AKT-eNOS Ras pathway, or the NF-kB pathway, NOS
inhibition has the potential to affect many components of tumor
maintenance and growth [2,6,10]. A recent study has shown NOS
inhibition to reduce lymph node metastasis from a peripheral ear
model of fibrosarcoma [44]. Consideration thus should be given as
to how decreased tumor burden following combined treatment
corresponds to increased survival. A similar increase in survival
does not follow with the decreased tumor burden observed with
either L-NNA or IR alone, as such the role of NO in other
pathologic processes such as tumor metastasis and cell migration
need consideration [45,49].
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